The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells
Top Cited Papers
- 1 April 2003
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 63 (4) , 908-914
- https://doi.org/10.1124/mol.63.4.908
Abstract
This study investigates the effects of SR141716, a selective CB1 receptor antagonist that reduces food intake and body weight of rodents, on Acrp30 mRNA expression in adipose tissue. Acrp30, a plasma protein exclusively expressed and secreted by adipose tissue, has been shown to induce free fatty acid oxidation, hyperglycemia and hyperinsulinemia decrease, and body weight reduction. We report thatN-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR141716) treatment once daily (10 mg/kg/d, i.p.) from 2 to 14 days reduced body weight and stimulated Acrp30 mRNA expression in adipose tissue of obese Zucker (fa/fa) rats. In parallel, the hyperinsulinemia associated with this animal model was reduced by SR141716 treatment. In cultured mouse adipocytes (3T3 F442A), SR141716 (25 to 100 nM) also induced an overexpression of Acrp30 mRNA and protein. In addition, in adipose tissue of CB1-receptor knockout mice, SR141716 had no effect on Acrp30 mRNA expression, demonstrating a CB1 receptor mediating effect. Furthermore, RT-PCR analysis revealed that rat adipose tissue and 3T3 F442A adipocytes expressed CB1 receptor mRNA. Relative quantification of this expression revealed an up-regulation (3- to 4-fold) of CB1 receptor mRNA expression in adipose tissue of obese (fa/fa) rats and in differentiated 3T3 F442A adipocytes compared with lean rats and undifferentiated adipocytes, respectively. Western blot analysis revealed the presence of CB1receptors in 3T3 F442A adipocytes, and their expression was up-regulated in differentiated cells. These results show that SR141716 stimulated Acrp30 mRNA expression in adipose tissue by an effect on adipocytes, and reduced hyperinsulinemia in obese (fa/fa) rats. These hormonal regulations may participate in the body weight reduction induced by SR141716 and suggest a role of metabolic regulation in the antiobesity effect of SR141716.Keywords
This publication has 35 references indexed in Scilit:
- The adipocyte-secreted protein Acrp30 enhances hepatic insulin actionNature Medicine, 2001
- Patent focus on new anti-obesity agents: September 1999 - February 2000Expert Opinion on Therapeutic Patents, 2000
- Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weightBrain Research, 1999
- Annual Deaths Attributable to Obesity in the United StatesJAMA, 1999
- Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in ObesityBiochemical and Biophysical Research Communications, 1999
- Cyclic guanosylmonophosphate urinary excretion in parasympathicomimetic or parasympatholytic syndromes induced by reserpine or diphemanil-methylsulfateLife Sciences, 1998
- Involvement of central cannabinoid (CB 1 ) receptors in the establishment of place conditioning in ratsPsychopharmacology, 1998
- A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1Journal of Biological Chemistry, 1997
- Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptorsPsychopharmacology, 1997
- Insulin Normalization as an Approach to the Pharmacological Treatment of ObesityObesity Research, 1995